PE20080428A1 - Vacunas para la malaria - Google Patents
Vacunas para la malariaInfo
- Publication number
- PE20080428A1 PE20080428A1 PE2007000913A PE2007000913A PE20080428A1 PE 20080428 A1 PE20080428 A1 PE 20080428A1 PE 2007000913 A PE2007000913 A PE 2007000913A PE 2007000913 A PE2007000913 A PE 2007000913A PE 20080428 A1 PE20080428 A1 PE 20080428A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- vivax
- repetition
- region
- seq
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 241000223810 Plasmodium vivax Species 0.000 abstract 4
- -1 3D-MPL Substances 0.000 abstract 2
- 101710117490 Circumsporozoite protein Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 101710137302 Surface antigen S Proteins 0.000 abstract 1
- 102400000700 Tumor necrosis factor, membrane form Human genes 0.000 abstract 1
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA PROTEINA DE FUSION HIBRIDA INMUNOGENICA QUE COMPRENDE: A) AL MENOS UNA UNIDAD DE REPETICION DERIVADA DE LA REGION DE REPETICION DE UNA PROTEINA DE CIRCUMSPOROZOITO DE TIPO I DE P. VIVAX SELECCIONADA ENTRE UNO O MAS MONOMEROS DE LA SEQ ID Nº 3 A 9; B) AL MENOS UNA UNIDAD DE REPETICION DERIVADA DE LA REGION DE REPETICION DE UNA PROTEINA DE CIRCUMSPOROZOITO DE TIPO II DE P. VIVAX SELECCIONADO ENTRE 1 0 MAS MONOMEROS DE SEQ ID Nº10 o 14; C) ANTIGENO S DE SUPERFICIE DERIVADO DEL VIRUS DE HEPATITIS B, O UN FRAGMENTO DEL MISMO SELECCIONADO DE DBP, PvTRAP, PvMSP2, PvMSP4, ENTRE OTROS; D) UN ADYUVANTE SELECCIONADO DE SAPONINA, 3D-MPL, LIPOSOMA, ISCOM; TENSIOACTIVO SELECCIONADO ENTRE TWEEN 20, BRIJI, POLIETILENGLICOL,. DICHA PROTEINA COMPRENDE ADEMAS UN FRAGMENTO N TERMINAL DE LA PROTEINA CS DE P. VIVAX CONOCIDO COMO LA REGION (I) TAL COMO SE MUESTRA EN LA SEQ ID Nº 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE MALARIA PROVOCADA POR PLASMODIUM VIVAX
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0614254.1A GB0614254D0 (en) | 2006-07-18 | 2006-07-18 | Vaccine |
GB0614476A GB0614476D0 (en) | 2006-07-20 | 2006-07-20 | Vaccine |
GB0614473A GB0614473D0 (en) | 2006-07-20 | 2006-07-20 | Vaccines |
GB0615115A GB0615115D0 (en) | 2006-07-28 | 2006-07-28 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080428A1 true PE20080428A1 (es) | 2008-05-15 |
Family
ID=38957130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000913A PE20080428A1 (es) | 2006-07-18 | 2007-07-16 | Vacunas para la malaria |
Country Status (22)
Country | Link |
---|---|
US (2) | US9592282B2 (es) |
EP (2) | EP2040742B1 (es) |
JP (2) | JP5222289B2 (es) |
KR (2) | KR20090094213A (es) |
AR (1) | AR061894A1 (es) |
AU (2) | AU2007276219B2 (es) |
BR (2) | BRPI0715581A2 (es) |
CA (2) | CA2657353A1 (es) |
CO (2) | CO6150189A2 (es) |
CR (2) | CR10561A (es) |
EA (2) | EA200900033A1 (es) |
ES (2) | ES2525732T3 (es) |
IL (2) | IL196410A0 (es) |
MA (2) | MA30671B1 (es) |
MX (2) | MX2009000650A (es) |
NO (2) | NO20090177L (es) |
NZ (2) | NZ574238A (es) |
PE (1) | PE20080428A1 (es) |
SG (2) | SG173363A1 (es) |
TW (1) | TW200819462A (es) |
WO (2) | WO2008009650A2 (es) |
ZA (1) | ZA200900386B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
PL209133B1 (pl) | 2001-11-21 | 2011-07-29 | Univ Pennsylvania | Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie |
BRPI0715581A2 (pt) * | 2006-07-18 | 2013-04-24 | Glaxosmithkline Biolog Sa | proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna |
UY31510A1 (es) * | 2007-12-06 | 2009-08-03 | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
TW200940087A (en) * | 2007-12-24 | 2009-10-01 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
ES2532015T3 (es) * | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
US8784832B2 (en) | 2011-08-19 | 2014-07-22 | University Of South Florida (A Florida Non-Profit Corporation) | Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
WO2013123412A1 (en) * | 2012-02-17 | 2013-08-22 | Children's Medical Center Corporation | Conformation-stabilized trap antigens |
WO2014111733A1 (en) * | 2013-01-21 | 2014-07-24 | Isis Innovation Limited | Composition and uses thereof |
EP3213638A1 (en) | 2016-03-01 | 2017-09-06 | Coöperatie Avebe U.A. | Vegan cheese analogue |
GB201608821D0 (en) | 2016-05-19 | 2016-07-06 | Isis Innovation | Vaccines |
MX2019006728A (es) | 2016-12-07 | 2019-12-02 | Glaxosmithkline Biologicals Sa | Nuevo proceso. |
EP3559669A4 (en) * | 2016-12-23 | 2020-11-18 | The Walter and Eliza Hall Institute of Medical Research | SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PLASMODIUM VIVAX |
JP7305057B2 (ja) | 2020-09-16 | 2023-07-07 | 三菱電機株式会社 | 前照灯装置 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
ATE118784T1 (de) * | 1985-07-12 | 1995-03-15 | Univ New York | Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen. |
US4826957A (en) * | 1985-07-12 | 1989-05-02 | New York University | Immunogenic recombinant yeast expression product and method for purifying it |
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
JPH0222300A (ja) * | 1987-02-02 | 1990-01-25 | Swiss Serum & Vaccine Inst Bern | 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法 |
US4997647A (en) * | 1987-03-30 | 1991-03-05 | New York University | Vaccine against the sporozoite stage of malaria |
JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US4977647A (en) * | 1989-10-27 | 1990-12-18 | D.B. Industries, Inc. | Double locking snap hook |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
DK0614465T3 (da) | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybridprotein mellem CS fra Plasmodium og HBsAg |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
DE69434221T2 (de) * | 1993-09-10 | 2006-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bindungsdomänen von Plasmodius Vivax und Plasmodium Falciparum Erythrozyten bindenden Proteinen |
DK0729473T3 (da) | 1993-11-17 | 2000-10-30 | Deutsche Om Arzneimittel Gmbh | Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
US20030133944A1 (en) | 2001-04-05 | 2003-07-17 | Smithkline Beecham Biologicals S.A. | Vaccine composition against malaria |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
AU761396B2 (en) | 1998-06-30 | 2003-06-05 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
KR20000020497A (ko) | 1998-09-21 | 2000-04-15 | 임채승 | 말라리아의 검출방법 |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
AU1600401A (en) * | 1999-11-12 | 2001-06-06 | Chinese University Of Hong Kong, The | Malaria vaccine |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
GB0027088D0 (en) | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
US6942866B2 (en) * | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
EP1201250A1 (en) * | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
CA2451864C (en) | 2001-06-22 | 2013-01-15 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
NZ539509A (en) | 2002-10-23 | 2008-05-30 | Glaxosmithkline Biolog Sa | Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine |
SG156535A1 (en) | 2002-12-17 | 2009-11-26 | Crucell Holland Bv | Recombinant viral-based malaria vaccines |
EP1636370B1 (en) | 2003-06-20 | 2014-04-16 | The Trustees of The University of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
JP4898434B2 (ja) | 2003-06-20 | 2012-03-14 | シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー | B型肝炎ウィルスの新規の表面タンパク質(HBsAg)変異体 |
US20050233435A1 (en) * | 2003-09-04 | 2005-10-20 | Nyu Medical Center | Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
US20060041248A1 (en) * | 2004-08-23 | 2006-02-23 | Patton David L | Pharmaceutical compositions delivery system and methods |
GB0420634D0 (en) | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
AU2006214694B2 (en) * | 2005-01-18 | 2011-09-08 | Walter Reed Army Institute Of Research | A plasmodium vivax hybrid circumsporozoite protein and vaccine |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
BRPI0715581A2 (pt) * | 2006-07-18 | 2013-04-24 | Glaxosmithkline Biolog Sa | proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna |
TW200940087A (en) * | 2007-12-24 | 2009-10-01 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
-
2007
- 2007-07-16 BR BRPI0715581-6A patent/BRPI0715581A2/pt not_active IP Right Cessation
- 2007-07-16 NZ NZ574238A patent/NZ574238A/en not_active IP Right Cessation
- 2007-07-16 US US12/374,214 patent/US9592282B2/en not_active Expired - Fee Related
- 2007-07-16 AU AU2007276219A patent/AU2007276219B2/en not_active Ceased
- 2007-07-16 PE PE2007000913A patent/PE20080428A1/es not_active Application Discontinuation
- 2007-07-16 EP EP07787564.9A patent/EP2040742B1/en active Active
- 2007-07-16 WO PCT/EP2007/057296 patent/WO2008009650A2/en active Application Filing
- 2007-07-16 WO PCT/EP2007/057301 patent/WO2008009652A2/en active Application Filing
- 2007-07-16 CA CA002657353A patent/CA2657353A1/en not_active Abandoned
- 2007-07-16 SG SG2011050150A patent/SG173363A1/en unknown
- 2007-07-16 KR KR1020097003262A patent/KR20090094213A/ko not_active Application Discontinuation
- 2007-07-16 JP JP2009519966A patent/JP5222289B2/ja not_active Expired - Fee Related
- 2007-07-16 ES ES07787564.9T patent/ES2525732T3/es active Active
- 2007-07-16 AU AU2007276217A patent/AU2007276217B2/en not_active Ceased
- 2007-07-16 SG SG201105140-6A patent/SG173377A1/en unknown
- 2007-07-16 EP EP07787569.8A patent/EP2040743B1/en active Active
- 2007-07-16 NZ NZ574239A patent/NZ574239A/en not_active IP Right Cessation
- 2007-07-16 US US12/374,238 patent/US9364525B2/en not_active Expired - Fee Related
- 2007-07-16 ES ES07787569.8T patent/ES2437082T3/es active Active
- 2007-07-16 CA CA002657279A patent/CA2657279A1/en not_active Abandoned
- 2007-07-16 MX MX2009000650A patent/MX2009000650A/es active IP Right Grant
- 2007-07-16 TW TW096125902A patent/TW200819462A/zh unknown
- 2007-07-16 EA EA200900033A patent/EA200900033A1/ru unknown
- 2007-07-16 JP JP2009519964A patent/JP5592110B2/ja not_active Expired - Fee Related
- 2007-07-16 BR BRPI0714326-5A patent/BRPI0714326A2/pt not_active IP Right Cessation
- 2007-07-16 MX MX2009000655A patent/MX2009000655A/es active IP Right Grant
- 2007-07-16 KR KR1020097003247A patent/KR20090092752A/ko not_active Application Discontinuation
- 2007-07-16 EA EA200900032A patent/EA200900032A1/ru unknown
- 2007-07-17 AR ARP070103168A patent/AR061894A1/es unknown
-
2009
- 2009-01-08 IL IL196410A patent/IL196410A0/en unknown
- 2009-01-13 NO NO20090177A patent/NO20090177L/no not_active Application Discontinuation
- 2009-01-13 IL IL196471A patent/IL196471A0/en unknown
- 2009-01-13 NO NO20090178A patent/NO20090178L/no not_active Application Discontinuation
- 2009-01-14 CR CR10561A patent/CR10561A/es not_active Application Discontinuation
- 2009-01-14 CR CR10555A patent/CR10555A/es not_active Application Discontinuation
- 2009-01-16 ZA ZA2009/00386A patent/ZA200900386B/en unknown
- 2009-01-20 CO CO09004463A patent/CO6150189A2/es unknown
- 2009-01-20 CO CO09004461A patent/CO6150187A2/es unknown
- 2009-02-27 MA MA31672A patent/MA30671B1/fr unknown
- 2009-02-27 MA MA31671A patent/MA30670B1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080428A1 (es) | Vacunas para la malaria | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
EA201001491A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
NO20072470L (no) | Malariaigangsetter/forsterkervaksine | |
PE20140844A1 (es) | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica | |
DK1951296T4 (da) | Celleafledte viral vacciner med lave niveauer af restcelle-DNA | |
DK1856159T3 (da) | Kimære, rekombinante antigener af Toxoplasma gondii | |
WO2007011904A3 (en) | Recombinant flu vaccines | |
PE20100658A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL | |
PE20142330A1 (es) | Vacuna de peptido ch3 de ige | |
TR201901649T4 (tr) | Nematodların ve toprak kaynaklı hastalıkların kontrolüne yönelik bileşimler ve yöntemler. | |
PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
PE20070203A1 (es) | Vacuna anti-malaria que comprende un antigeno de plasmodium | |
WO2009022236A3 (en) | Immunogen platform | |
PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
EA201170812A1 (ru) | Способы и композиции для применения вакцины против кокцидиоза | |
WO2009130588A3 (en) | Codon-optimzed hepatitis b virus core antigen (hbcag) | |
UA108081C2 (uk) | Модифікація рекомбінантного аденовірусу імуногенними епітопами білка circumsporozoite плазмодія | |
PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
BRPI0613362A8 (pt) | polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção | |
AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
PE20140520A1 (es) | Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento | |
AR086207A1 (es) | Composiciones y metodos | |
CR11537A (es) | Vacuna | |
WO2006091455A3 (en) | Molecular scaffolds for hiv-1 immunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |